HomeAI Core TechnologiesFOXO Technologies Unveils Plans for New Direct-to Consumer Offering Combining the Company’s...

FOXO Technologies Unveils Plans for New Direct-to Consumer Offering Combining the Company’s Epigenetic Data with the Power of AI

Announces Collaboration and Secures Exclusive License with KR8.ai to Power New Epigenetic Wellness Solutions

FOXO Technologies Inc., a leader in the field of commercializing epigenetic biomarker technology, today announced plans for a new subscription-based, direct-to-consumer product offering that will provide personalized health and wellness recommendations, by combining: (i) FOXO’s machine learning models to analyze epigenetic biomarkers; (ii) the Company’s expertise and algorithms correlating epigenetic analysis with health outcomes; and (iii) published, peer-reviewed, clinical data and other verified, third-party health resources. In connection with the new offering, the Company also announced it has formed a collaboration with KR8.ai Inc. (“KR8”) and secured an exclusive license to KR8’s AI-based software to support the development and commercial launch of the new health and wellness offering.

Mark White, Interim CEO of FOXO Technologies, stated, “We are excited to formally unveil plans for our new direct-to-consumer offering. This strategy is designed to leverage our epigenetic data and analytics, which we believe reflects our core strength and includes some of the most advanced capabilities in the industry. Epigenetics is central to understanding how genes are regulated and how lifestyle and environmental influences interact with our biological systems. Fully unlocking the value of epigenetic data has been a challenge due to complexities in data processing and interpretation. By integrating KR8’s advanced AI software, we intend to launch a best-in-class health and wellness offering, including a new consumer app, which will provide individuals with personalized insights to understand their biological age and optimize health. Getting started would simply require users to send a saliva or blood sample and the technology will then combine this information with user health stats, from readily available sources and third-party apps. Moreover, we intend to combine these inputs, through the power of AI, with massive health data sets, such as peer-reviewed clinical studies and other verified health resources, to provide a comprehensive risk analysis and actionable health insights. By leveraging the KR8 software with FOXO’s epigenetic expertise and growing patent estate, we look forward to empowering consumers to better manage their own health.”

“To enhance our commercial launch, we look forward to integrating KR8’s AI-driven analytic software and proprietary algorithms to cost-effectively drive social media campaigns, as well as leverage their broad network of social media influencers with a goal of rapidly scaling FOXO’s new direct-to-consumer offering. They have a proven track record working with leading brands, and I truly believe they are the ideal partner for this new endeavor. According to Verified Market Research, the Health and Fitness App Market size was valued at $8.2 billion in 2022 and is projected to reach $35.7 billion by 2030. We believe we are well positioned to capture a meaningful share of this market through an unparalleled offering that goes way beyond traditional health apps, coupled with a cost-effective go-to-market strategy. We look forward to providing regular updates on our progress in the weeks and months ahead, including the product branding, integration with other health apps, launch dates and much more,” concluded Mr. White.

Spencer Cliff Christopher, Founder and Chief Technology Officer of KR8, stated, “We are thrilled to announce our strategic partnership with FOXO, an exemplary leader within the epigenetic domain. The integration of KR8’s robust artificial intelligence capabilities with FOXO’s unparalleled expertise in genetics is poised to redefine the standards of wellness coaching. This collaboration underscores our unwavering dedication to innovation and our commitment to empowering individuals with personalized, data-driven insights for their health and well-being. As we embark on this exciting venture, we are confident that this synergy of genetic insight and precision AI will establish a new standard in personalized wellness, offering users an unmatched level of guidance and support. We look forward to not just using AI as a tool, but as a companion in people’s health journey.”